WEREWOLF THERAPEUTICS INC. - COMMON STOCK

Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 05:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08 авг 2024 04:05:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

25 июн 2024 04:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

01 июн 2024 05:59:59 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

30 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

23 май 2024 14:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

03 май 2024 04:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 07:05:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

23 апр 2024 05:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

05 апр 2024 13:30:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

04 апр 2024 13:30:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 мар 2024 04:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

06 мар 2024 05:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

05 мар 2024 13:30:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

08 янв 2024 04:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

22 ноя 2023 04:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

14 ноя 2023 13:25:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

03 ноя 2023 04:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

31 окт 2023 06:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

27 сен 2023 06:00:00 Источник Nasdaq GlobeNewswire